ROI funded an RTOG analysis of its data set 0126, Phase III randomized trial data, which examined patient outcomes from treatment for prostate cancer with IMRT vs. high dose 3-D CRT. Specific aims were to examine toxicity levels with each type of treatment for bladder, bowel and erectile function; quality of life (QOL) as reported by patients; and any correlations among dosage, toxicity, treatment plans and patient reported outcomes.
The final results were presented at ASTRO's Annual Meeting in October 2012. The complete analysis was published in the December 1, 2013 edition of the International Journal of Radiation Oncology
• Biology • Physics (Red Journal), the official scientific journal of the
American Society for Radiation Oncology (ASTRO).
For more information, contact Emily Connelly.